Compare Baker Hughes Co (BKR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baker Hughes Co vs Sana Biotechnology Inc — how do they compare? Baker Hughes Co trades at $64.65 (market cap $64.34B), while Sana Biotechnology Inc trades at $3.77 (market cap $1.13B). The key difference: Baker Hughes Co is far larger — about 56.9× Sana Biotechnology Inc's market cap, and Baker Hughes Co pays a 1.42% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| BKR | SANA | |
|---|---|---|
Market Cap | $64.34B | $1.13B |
Sector | Energy | Health |
52-Week High | $69.67 | $5.92 |
52-Week Low | $42.51 | $2.68 |
Enterprise Value | $64.86B | $1.05B |
Dividend Yield | 1.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baker Hughes (BKR) trades at $64.94, up 1.35% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company demonstrates robust fundamentals with a P/E of 20.84, ROE of 16.47%, and positive cash flow trends. Recent news highlights major contract wins in subsea systems and LNG technology, signaling strong demand for its energy infrastructure solutions.
The outlook for BKR is positive, supported by analyst consensus and operational strength, though risks include integration challenges from acquisitions and potential volatility in oil & gas spending. The stock presents an opportunity for growth investors seeking exposure to energy technology, with a consensus price target of $73.25 implying potential upside.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
